0001209191-22-059425.txt : 20221202
0001209191-22-059425.hdr.sgml : 20221202
20221202163038
ACCESSION NUMBER: 0001209191-22-059425
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221130
FILED AS OF DATE: 20221202
DATE AS OF CHANGE: 20221202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Domzalski David
CENTRAL INDEX KEY: 0001727794
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38356
FILM NUMBER: 221442377
MAIL ADDRESS:
STREET 1: C/O FOAMIX PHARMACEUTICALS LTD.
STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VYNE Therapeutics Inc.
CENTRAL INDEX KEY: 0001566044
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 453757789
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 685 ROUTE 202/206, SUITE 301A
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
BUSINESS PHONE: 800-775-7936
MAIL ADDRESS:
STREET 1: 685 ROUTE 202/206, SUITE 301A
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: Menlo Therapeutics Inc.
DATE OF NAME CHANGE: 20180201
FORMER COMPANY:
FORMER CONFORMED NAME: Menlo Therapeutics, Inc.
DATE OF NAME CHANGE: 20170728
FORMER COMPANY:
FORMER CONFORMED NAME: Tigercat Pharma, Inc.
DATE OF NAME CHANGE: 20130104
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-30
0
0001566044
VYNE Therapeutics Inc.
VYNE
0001727794
Domzalski David
C/O VYNE THERAPEUTICS INC.
685 ROUTE 202/206, SUITE 301A
BRIDGEWATER
NJ
08807
1
1
0
0
President and CEO
Common Stock
2022-11-30
5
A
0
E
34705
0.1977
A
1074975
D
These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on June 1, 2022 and ending on November 30, 2022 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on November 30, 2022 (the last trading day of the offering period). The reporting person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year.
/s/ Mutya Harsch, attorney-in-fact for David Domzalski
2022-12-02